Diligence memo · auto-generated · as of July 2, 2026
Antlia Bioscience, Inc.
Antlia Bioscience, Inc. looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Antlia Bioscience, Inc. operates in Biotech, based in ENCINITAS.
Sub-sector tags: biotech.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Antlia Bioscience, Inc. has raised $887K in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $680K on 2022-04-13.
Most recent recorded round closed around 2022-04-13.
Valuation (modeled)modeled
Provath models Antlia Bioscience, Inc. at approximately $12M (range $363K–$82M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 6.78× the median modeled value of Pre-Seed Biotech companies in 2022–2024 (5 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 18 months.
Last raise 4.2 yr ago; this sector typically re-raises about every 11 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 3.3× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 73% of Biotech peers (233 compared).
Modeled value ranks above 76% of those peers.
Closest niche peers: Innovation1 Biotech Inc., Bodhi Tree Biotechnology Inc, Biotech Social Inc., X1 Biotech Inc..
Peoplefiled
1 named person on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.